(EVK) Evonik Industries - Ratings and Ratios
Specialty Chemicals, Additives, Silicas, Polymers, Catalysts
EVK EPS (Earnings per Share)
EVK Revenue
Description: EVK Evonik Industries
Evonik Industries AG is a global specialty chemicals company operating across various regions, including Asia-Pacific, Europe, and the Americas. The company is divided into four main business segments: Specialty Additives, Nutrition & Care, Smart Materials, and Technology & Infrastructure, each catering to diverse industries such as coatings, animal nutrition, pharmaceuticals, and energy management.
The companys product portfolio includes a wide range of specialty chemicals and materials, such as additives for polyurethane foams, pharmaceutical active ingredients, and inorganic materials like fumed silicas. Evoniks offerings are used in various applications, including coatings, adhesives, composites, and medical devices. The companys Technology & Infrastructure segment provides services like energy management, process safety, and logistics support to the chemical industry.
From a financial perspective, Evonik has a market capitalization of approximately 8.23 billion EUR, with a price-to-earnings ratio of 27.18 and a forward P/E of 19.92. The companys return on equity is 3.31%. To further analyze the companys performance, we can look at additional key performance indicators (KPIs) such as revenue growth, EBITDA margin, and debt-to-equity ratio. For instance, Evoniks revenue growth has been driven by its focus on innovation and expansion into emerging markets. The companys EBITDA margin is around 15-20%, indicating a relatively stable profitability. The debt-to-equity ratio is approximately 0.5, suggesting a moderate level of leverage.
To evaluate Evoniks stock performance, we can examine its price movement and trading metrics. The stocks 52-week high and low are 20.95 and 15.36, respectively, with a current price of 18.01. The short-term moving averages (SMA20 and SMA50) indicate a relatively stable trend, while the long-term SMA200 suggests a slightly bullish outlook. Further analysis of the stocks trading metrics, such as trading volume and relative strength index (RSI), can provide additional insights into its market sentiment and potential price movements.
EVK Stock Overview
| Market Cap in USD | 9,130m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
EVK Stock Ratings
| Growth Rating | -16.1% |
| Fundamental | 48.2% |
| Dividend Rating | 65.6% |
| Return 12m vs S&P 500 | -24.7% |
| Analyst Rating | - |
EVK Dividends
| Dividend Yield 12m | 6.78% |
| Yield on Cost 5y | 6.47% |
| Annual Growth 5y | 0.35% |
| Payout Consistency | 96.7% |
| Payout Ratio | 70.1% |
EVK Growth Ratios
| Growth Correlation 3m | -85.5% |
| Growth Correlation 12m | -15.6% |
| Growth Correlation 5y | -42.9% |
| CAGR 5y | -1.80% |
| CAGR/Max DD 5y | -0.04 |
| Sharpe Ratio 12m | -0.38 |
| Alpha | -21.22 |
| Beta | 0.325 |
| Volatility | 23.32% |
| Current Volume | 1084.8k |
| Average Volume 20d | 1016.1k |
| Stop Loss | 15.9 (-3.6%) |
| Signal | -1.50 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (424.0m TTM) > 0 and > 6% of Revenue (6% = 882.4m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -3.99pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.74% (prev 11.17%; Δ 0.57pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 1.32b > Net Income 424.0m (YES >=105%, WARN >=100%) |
| Net Debt (-379.0m) to EBITDA (1.93b) ratio: -0.20 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.45 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (461.5m) change vs 12m ago -0.96% (target <= -2.0% for YES) |
| Gross Margin 24.69% (prev 22.45%; Δ 2.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 74.92% (prev 74.74%; Δ 0.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.87 (EBITDA TTM 1.93b / Interest Expense TTM 214.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.96
| (A) 0.09 = (Total Current Assets 5.60b - Total Current Liabilities 3.87b) / Total Assets 19.05b |
| (B) 0.39 = Retained Earnings (Balance) 7.50b / Total Assets 19.05b |
| (C) 0.04 = EBIT TTM 829.0m / Avg Total Assets 19.63b |
| (D) 0.76 = Book Value of Equity 7.96b / Total Liabilities 10.49b |
| Total Rating: 2.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 48.20
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 4.27% = 2.14 |
| 3. FCF Margin 3.21% = 0.80 |
| 4. Debt/Equity 0.42 = 2.41 |
| 5. Debt/Ebitda 1.86 = 0.28 |
| 6. ROIC - WACC -0.46% = -0.58 |
| 7. RoE 4.75% = 0.40 |
| 8. Rev. Trend -77.39% = -3.87 |
| 9. Rev. CAGR -11.38% = -1.90 |
| 10. EPS Trend 34.48% = 0.86 |
| 11. EPS CAGR -18.74% = -2.34 |
What is the price of EVK shares?
Over the past week, the price has changed by -4.13%, over one month by -7.46%, over three months by -13.44% and over the past year by -11.93%.
Is Evonik Industries a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EVK is around 16.17 EUR . This means that EVK is currently overvalued and has a potential downside of -1.94%.
Is EVK a buy, sell or hold?
What are the forecasts/targets for the EVK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20.6 | 24.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 17.5 | 6.1% |
EVK Fundamental Data Overview
Market Cap EUR = 7.84b (7.84b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 379.0m EUR (last quarter)
P/E Trailing = 17.9355
P/E Forward = 19.9203
P/S = 0.533
P/B = 0.9096
P/EG = 5.0637
Beta = 0.942
Revenue TTM = 14.71b EUR
EBIT TTM = 829.0m EUR
EBITDA TTM = 1.93b EUR
Long Term Debt = 3.59b EUR (from longTermDebt, last quarter)
Short Term Debt = unknown (0.0)
Debt = 3.59b EUR (Calculated: Short Term 0.0 + Long Term 3.59b)
Net Debt = -379.0m EUR (from netDebt column, last quarter)
Enterprise Value = 11.05b EUR (7.84b + Debt 3.59b - CCE 379.0m)
Interest Coverage Ratio = 3.87 (Ebit TTM 829.0m / Interest Expense TTM 214.0m)
FCF Yield = 4.27% (FCF TTM 472.0m / Enterprise Value 11.05b)
FCF Margin = 3.21% (FCF TTM 472.0m / Revenue TTM 14.71b)
Net Margin = 2.88% (Net Income TTM 424.0m / Revenue TTM 14.71b)
Gross Margin = 24.69% ((Revenue TTM 14.71b - Cost of Revenue TTM 11.08b) / Revenue TTM)
Tobins Q-Ratio = 1.39 (Enterprise Value 11.05b / Book Value Of Equity 7.96b)
Interest Expense / Debt = 1.56% (Interest Expense 56.0m / Debt 3.59b)
Taxrate = 44.70% (from yearly Income Tax Expense: 194.0m / 434.0m)
NOPAT = 458.4m (EBIT 829.0m * (1 - 44.70%))
Current Ratio = 1.45 (Total Current Assets 5.60b / Total Current Liabilities 3.87b)
Debt / Equity = 0.42 (Debt 3.59b / last Quarter total Stockholder Equity 8.49b)
Debt / EBITDA = 1.86 (Net Debt -379.0m / EBITDA 1.93b)
Debt / FCF = 7.60 (Debt 3.59b / FCF TTM 472.0m)
Total Stockholder Equity = 8.93b (last 4 quarters mean)
RoA = 2.23% (Net Income 424.0m, Total Assets 19.05b )
RoE = 4.75% (Net Income TTM 424.0m / Total Stockholder Equity 8.93b)
RoCE = 6.62% (Ebit 829.0m / (Equity 8.93b + L.T.Debt 3.59b))
RoIC = 4.75% (NOPAT 458.4m / Invested Capital 9.64b)
WACC = 5.22% (E(7.84b)/V(11.42b) * Re(7.21%)) + (D(3.59b)/V(11.42b) * Rd(1.56%) * (1-Tc(0.45)))
Shares Correlation 5-Years: -89.40 | Cagr: -0.45%
Discount Rate = 7.21% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.62% ; FCFE base≈805.6m ; Y1≈824.5m ; Y5≈916.2m
Fair Price DCF = 34.63 (DCF Value 16.14b / Shares Outstanding 466.0m; 5y FCF grow 2.21% → 3.0% )
Revenue Correlation: -77.39 | Revenue CAGR: -11.38%
Rev Growth-of-Growth: 9.72
EPS Correlation: 34.48 | EPS CAGR: -18.74%
EPS Growth-of-Growth: 112.1